EP3371225A2 - Dipeptidyl peptidase-4 et périostine utilisées comme prédicteurs d'une réponse clinique à des agents thérapeutiques ciblés sur les éosinophiles dans des maladies éosinophiles - Google Patents

Dipeptidyl peptidase-4 et périostine utilisées comme prédicteurs d'une réponse clinique à des agents thérapeutiques ciblés sur les éosinophiles dans des maladies éosinophiles

Info

Publication number
EP3371225A2
EP3371225A2 EP16822517.5A EP16822517A EP3371225A2 EP 3371225 A2 EP3371225 A2 EP 3371225A2 EP 16822517 A EP16822517 A EP 16822517A EP 3371225 A2 EP3371225 A2 EP 3371225A2
Authority
EP
European Patent Office
Prior art keywords
dpp4
patient
postn
eosinophil
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16822517.5A
Other languages
German (de)
English (en)
Inventor
Paul NEWBOLD
Koustubh Ranade
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of EP3371225A2 publication Critical patent/EP3371225A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

La présente invention concerne l'utilisation de niveaux d'expression génétique et/ou protéinique de la dipeptidyl peptidase-4 (DPP4/CD26) et de la périostine (POSTN) en tant que biomarqueurs périphériques pour des maladies ou des troubles éosinophiles, par exemple de l'asthme modéré à sévère. Des niveaux de DPP4 et/ou de POSTN supérieurs ou inférieurs à des niveaux seuils prédéfinis de DPP4 et/ou de POSTN peuvent être utilisés, par exemple, (i) pour déterminer l'éligibilité d'un patient à un certain traitement avec un antagoniste de l'IL-5R, par exemple, un anticorps anti-IL-5R tel que le benralizumab (MEDI-563), (ii) pour déterminer si un certain traitement d'une maladie ou d'un trouble éosinophile avec un antagoniste spécifique de l'IL-5R devrait être initié, arrêté ou modifié, (iii) pour diagnostiquer si une maladie ou un trouble éosinophile peut être traité ou non avec un antagoniste spécifique de l'IL-5R, (iv) pour établir un pronostic du résultat du traitement d'une maladie ou d'un trouble éosinophile avec un antagoniste spécifique de l'IL-5R, etc.
EP16822517.5A 2015-11-04 2016-11-03 Dipeptidyl peptidase-4 et périostine utilisées comme prédicteurs d'une réponse clinique à des agents thérapeutiques ciblés sur les éosinophiles dans des maladies éosinophiles Withdrawn EP3371225A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562250691P 2015-11-04 2015-11-04
PCT/IB2016/001726 WO2017077391A2 (fr) 2015-11-04 2016-11-03 Dipeptidyl peptidase-4 et périostine utilisées comme prédicteurs d'une réponse clinique à des agents thérapeutiques ciblés sur les éosinophiles dans des maladies éosinophiles

Publications (1)

Publication Number Publication Date
EP3371225A2 true EP3371225A2 (fr) 2018-09-12

Family

ID=57737757

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16822517.5A Withdrawn EP3371225A2 (fr) 2015-11-04 2016-11-03 Dipeptidyl peptidase-4 et périostine utilisées comme prédicteurs d'une réponse clinique à des agents thérapeutiques ciblés sur les éosinophiles dans des maladies éosinophiles

Country Status (6)

Country Link
EP (1) EP3371225A2 (fr)
JP (1) JP2018538249A (fr)
AU (1) AU2016349113A1 (fr)
CA (1) CA3002761A1 (fr)
HK (1) HK1255922A1 (fr)
WO (1) WO2017077391A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112654397A (zh) * 2018-09-05 2021-04-13 国家医疗保健研究所 用于治疗哮喘和过敏性疾病的方法和组合物
KR102527520B1 (ko) * 2020-09-16 2023-05-03 순천대학교 산학협력단 직업성 천식 진단용 조성물 및 이를 이용한 직업성 천식 진단방법
CA3232203A1 (fr) * 2021-09-22 2023-03-30 James MATTHAEI Marqueurs de surface cellulaire d'il5ra

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
TW311927B (fr) 1995-07-11 1997-08-01 Minnesota Mining & Mfg
JP3946256B2 (ja) 1995-09-11 2007-07-18 協和醗酵工業株式会社 ヒトインターロイキン５受容体α鎖に対する抗体
WO1998023289A1 (fr) 1996-11-27 1998-06-04 The General Hospital Corporation Modulation de la fixation de l'igg au fcrn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CA2402477A1 (fr) 2000-02-15 2001-08-23 Kyowa Hakko Kogyo Co., Ltd. Inducteur de l'apoptose specifique a l'eosinophilie
WO2004104216A2 (fr) * 2003-05-21 2004-12-02 Bayer Healthcare Ag Diagnostics et agents therapeutiques destines a des maladies liees a une dipeptidylpeptidase iv (dpp4)
US20050226867A1 (en) 2003-10-08 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. IL-5R-specific antibody composition
BRPI0517387A8 (pt) 2004-10-29 2017-07-11 Topigen Pharmaceuticals Inc Oligonucleotídeos anti-senso para o tratamento de alergia e proliferação de células neoplásicas
WO2007098065A2 (fr) 2006-02-17 2007-08-30 The United States Of America As Represented By The Department Of Veterans Affairs Isoformes de canaux sodium humains
WO2008091814A2 (fr) * 2007-01-22 2008-07-31 Wyeth Évaluation de l'asthme et d'une expression d'un gène dépendant d'un allergène
EP2068927B1 (fr) 2007-05-14 2015-10-21 MedImmune, LLC Methodes de reduction de niveaux d'eosinophiles
US7879553B2 (en) 2008-03-14 2011-02-01 Exagen Diagnostics, Inc. Biomarkers for inflammatory bowel disease and irritable bowel syndrome
EP2631302A3 (fr) 2008-03-31 2014-01-08 Genentech, Inc. Compositions et procédés pour traiter et diagnostiquer l'asthme
CA2734919C (fr) 2008-08-27 2016-08-16 Schering Corporation Formulations lyophilisees d'anticorps anti-il-23p19 modifies
US20100221752A2 (en) 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
US20100093552A1 (en) 2008-10-09 2010-04-15 Asit Panja Use and identification of biomarkers for gastrointestinal diseases
CA2741566A1 (fr) 2008-11-03 2010-06-03 Schering Corporation Biomarqueurs de maladie inflammatoire de l'intestin et procedes apparentes du traitement
WO2010129964A1 (fr) 2009-05-08 2010-11-11 The Board Of Trustees Of The University Of Illinois Cibles de médicament pour la prévention de l'arythmie dans une maladie cardiaque
EP2778685B1 (fr) 2009-06-25 2017-04-26 Nestec S.A. Procédés pour diagnostiquer le syndrome du côlon irritable
BR112012012513A2 (pt) 2009-11-25 2017-01-10 Prometheus Lab Inc método para diagnosticar síndrome do intestino irritável em um paciente, método para monitorar a progressão ou regressão da síndrome do intestino irritável em um paciente, e para designar uma terapia contra síndrome do intestino irritável a um paciente em necessidade do mesmo
DK2523688T3 (en) 2010-01-15 2017-12-04 Kirin-Amgen Inc ANTIBODY FORMULATION AND THERAPEUTIC REGIMENS
AU2011343570B2 (en) 2010-12-16 2016-11-03 Genentech, Inc. Diagnosis and treatments relating to TH2 inhibition
EP2661506A4 (fr) 2011-01-06 2014-11-19 Univ Illinois Variants d'épissage de scn5a destinés à être utilisés dans des procédés liés à une mort subite cardiaque et nécessité d'implantation de défibrillateurs cardiaques
EP2710383B1 (fr) 2011-05-16 2017-01-11 The University of Newcastle Efficacité d'un panel de biomarqueurs du syndrome du côlon irritable
US8961965B2 (en) 2011-05-18 2015-02-24 Medimmune, Llc Methods of diagnosing and treating pulmonary diseases or disorders
EP2834370B1 (fr) 2012-04-03 2019-01-02 The Regents Of The University Of Michigan Biomarqueur associé avec le syndrome du côlon irritable et la maladie de crohn
RU2020123894A (ru) 2013-08-12 2020-09-18 Астразенека Аб Способы нормализации симптомов астмы с применением бенрализумаба
SG11201600481UA (en) 2013-08-12 2016-02-26 Medimmune Llc Methods for reducing exacerbation rates of asthma using benralizumab
WO2015112970A1 (fr) * 2014-01-27 2015-07-30 Medimmune, Llc Dipeptidyl peptidase-4 (dpp4/cd26) comme biomarqueur périphérique de l'activation de l'il-13 dans des poumons asthmatiques
CA2936285A1 (fr) 2014-02-07 2015-08-13 Medimmune, Llc Nouvel essai biologique pour la detection de la periostine humaine

Also Published As

Publication number Publication date
JP2018538249A (ja) 2018-12-27
AU2016349113A1 (en) 2018-06-07
WO2017077391A3 (fr) 2017-06-29
HK1255922A1 (zh) 2019-09-06
CA3002761A1 (fr) 2017-05-11
WO2017077391A2 (fr) 2017-05-11

Similar Documents

Publication Publication Date Title
JP7153775B2 (ja) Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
US8961965B2 (en) Methods of diagnosing and treating pulmonary diseases or disorders
US20220144935A1 (en) Ccl20 as a predictor of clinical response to il23-antagonists
US10684292B2 (en) Methods for detection of emphysema
EP3685857A1 (fr) Dipeptidyl peptidase-4 (dpp4/cd26) comme biomarqueur périphérique de l'activation de l'il-13 dans des poumons asthmatiques
Murr et al. Cross-sectional association of salivary proteins with age, sex, body mass index, smoking, and education
WO2017077391A2 (fr) Dipeptidyl peptidase-4 et périostine utilisées comme prédicteurs d'une réponse clinique à des agents thérapeutiques ciblés sur les éosinophiles dans des maladies éosinophiles
US11275091B2 (en) SARS-COV-2 infection biomarkers and uses thereof
US20220373539A1 (en) Prediction of clinical response to il23-antagonists using il23 pathway biomarkers
EP3892280A2 (fr) Biomarqueurs d'une infection sars-cov-2 et leurs utilisations
Sidiropoulou et al. Long Term Immune and Epigenetic Dysregulation Following COVID-19: The Impact of Anti-IL-1 Treatment in the Post-Acute COVID Syndrome
Kang et al. The Association of Chronic Periodontitis as a Potential Risk Factor with Rheumatoid Arthritis: A Nested Case-Control Study Using a Korean National Health Screening Cohort
Khan Biomarkers of progressive lung fibrosis
Harries downloaded from the King’s Research Portal at https://kclpure. kcl. ac. uk/portal
WO2023055901A2 (fr) Méthodes de détermination de réactivité à des inhibiteurs de tyk2
Adcock et al. Mapping atopic dermatitis and anti-IL-22 response signatures to Type 2-low severe neutrophilic asthma

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180604

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1255922

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200603